Figure 1.

Proportion of participants reporting injecting drug use and sharing of injection equipment (A), median alcohol use (B), and proportion receiving opioid agonist treatment (OAT) and noninjecting drugs (C) at each visit, during and following direct-acting antiviral treatment for hepatitis C virus infection among people with recent injection drug use or receiving OAT recruited and followed in SIMPLIFY and D3FEAT (N = 190). Drug use outcomes and OAT refer to the past month and current period, respectively. Baseline visit refers to the date of treatment initiation. Follow-up periods 1, 2, and 3 correspond to weeks 60, 84, and 108 since treatment initiation, respectively. At screening, the sample size was 188 rather than 190 because behavioral data were unavailable for 2 participants recruited in D3FEAT. Abbreviations: BL, baseline; ETR, end of treatment; FU, follow-up; SCR, screening; SVR, sustained virological response; W, week.